Clinical Trial Detail

NCT ID NCT02452281
Title Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Rabih Said
Indications

melanoma

Therapies

Vitespen

Ipilimumab

Age Groups: adult

No variant requirements are available.